The discussion related to these products has changed dramatically from those had in previous years; in the past, the industry was discussing the regulatory framework and how the different regulatory agencies, from Mexico to Argentina, would regulate these new therapeutic options. Now, after the maturity of the laws and the construction of different regulatory pathways for biosimilars in most of the countries, the discussion has moved on to the different challenges that the industry, whether local or foreign, faces in commercializing biosimilars.

In most of the countries, governments are promoting the introduction of the biosimilars, due in part to the constraints they face in paying for high-cost innovative biologics, in addition to controlling healthcare spending linked with the increasing prevalence of diseases like cancer, diabetes, and other chronic conditions.
 
in the coming years, we will see a dynamic market with many players moving between countries with different regulatory frameworks and health system compositions, all trying to survive deep price reductions while demonstrating added value through the development of more real-world evidence or benefits in product improvements. At the same time, we will see these players increasing patient access to medicines. In the end, patients will benefit from these market dynamics with the introduction of therapeutic options that can help to overcome the access disparities that our region currently has.

Who will
you meet?

 

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

  • Biosimilars
  • Biobetters
  • Biotechnology
  • Biotherapeutics
  • Analytical science
  • Regulatory compliance
  • Quality Control
  • Clinical immunology
  • Scientific Affairs
  • Pharmacovigilance
  • Research
  • Regulatory
  • Business Development
  • Marketing

Speaker Board

Program at a Glance

Looking Back to Biosimilars in FDA / EMA

Beginning of the regulatory framework for Biosimilars in these agencies

Private Initiatives for Biosimilars Development

The advances that laboratories have made in Colombia

Biosimilars Latam Colombia 2020 Rundown

What happened in the last Biosimilars Forum.

Proper communication between Companies and Healthcare Professionals

Recommendations for a healthy and clear communication

Biosimilars success stories

Experiences from companies in other countries that can help the Colombian industry

Communication of Regulatory Agencies in Latam

The requirements and suggestions from ANMAT and DIGEMID

Biosimilars post-Pandemie

What is expected to happen once the pandemie is over

Full programme in the PDF Agenda

Download Agenda

Sponsors

Sartorius

Merck

We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.

Cytiva

Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.

LEI

The Laboratorios de Especialidades Inmunológicas (LEI) exist to ensure the Health of Mexico and the World through cutting-edge scientific analysis for the Human and Veterinary Pharmaceutical Industry, Cosmetics, as well as Clinical Analysis and Training. We are a Third Party Laboratory Authorized by COFEPRIS that since 1991 offers a unique catalog with the most innovative studies on the market at the service of your needs.

Photo Gallery from Previous Events

Testimonials

Previous Forums

Keep me updated